This FDA-approved drug, Votrient, for the treatment of Advanced Renal cell cancer and Advanced Soft tissue sarcoma, can also be repositioned for the targeting of YAP/TAZ-TEAD signalling in GC [181]. Here, YAP1 is linked to gastric cancer.